- $2.34bn
- $1.08bn
- $548.51m
Enrollment Complete in SAFFRON Global Phase III
Updates from R&D Event
HUTCHMED Presents Data at AACR NCI EORTC
Vesting of awards under Long Term Incentive Plan
Appointment of Independent Non-executive Director
Data to be Presented at the 2025 ESMO Congress
HUTCHMED Highlights Data to be Presented at ESMO
HUTCHMED to Present R&D Updates on October 31 2025
HUTCHMED Highlights Data to be Presented at CSCO
Directorate Change
Brief: Hutchmed (China) Says Weiguo Su Takes Leave As CEO Due To Health Reasons
HUTCHMED Completes Enrollment of Phase III Trial
Brief: Hutchmed (China) Updates FY25 Guidance For Oncology/Immunology Consol Rev To $270M - $350M
HUTCHMED (China) Posts H1 Net Income USD 455 Million
2025 Interim Results
Factbox: CK Hutchison: Global conglomerate caught in US-China trade spat
Hutchmed To Announce 2025 Half: Year Results
Update on Joint Corporate Brokers in London
Grant of Share Options and Awards under LTIP